Exploring the mechanism of Heidihuang Pill in the treatment of osteoporosis based on network pharmacology, molecular docking, and experimental validation
Peoniflorin, the main active ingredient in HP, acts on Akt1 and treats OP through the AGE-RAGE and HIF-1 signaling pathways. This study showed the precise molecular pathways and core therapeutic targets of HP in treating OP, and provides a scientific basis and new research direction for treating OP with TCM.
Authors
- Zenghui Tian (ORCID: https://orcid.org/0000-0002-2462-1077)
- Farong Zhang
- Kaiying Cui (ORCID: https://orcid.org/0009-0000-4312-0895)
- Yungang Chen
- Yanke Hao (ORCID: https://orcid.org/0009-0002-5105-1740)
- Yingying Li (ORCID: https://orcid.org/0000-0003-3243-1975)
- Guoyan Liu (ORCID: https://orcid.org/0000-0001-8879-6143)
- Yuxiao Tian
Institutions
- Shandong University of Traditional Chinese Medicine (CN)
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-12-15
- DOI
- https://doi.org/10.3389/fendo.2025.1664254
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00